ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2884

Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus

Neelakshi R. Jog1, Richard C. Pelikan1, Melissa Bebak2, Joel M. Guthridge3, Judith A. James1 and Patrick M. Gaffney1, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma city, OK, 3Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: epigenetics and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that involves multiple organ systems and periods of variable disease activity. Although SLE, especially in patients with high disease activity, is often associated with increased circulating pro-inflammatory cytokines, a clear understanding of immune dysfunction preceding and during high disease activity is lacking. The identification of genes and gene pathways that are differentially regulated between SLE and healthy individuals, as well as between patients with varying disease activity, may allow better selection of directed therapeutics and development of new targets. To address this knowledge gap, we determined the chromatin accessibility landscape of three distinct compartments of the lupus immune system using the ‘Assay for Transposase Accessible Chromatin Sequencing’ (ATAC-seq) method.

Methods: Monocytes, B cells, and T cells were sorted by flow cytometry from frozen PBMCs of 9 SLE patients and 5 matched controls. Sorted cell fractions were processed for high-throughput open chromatin profiling by ATAC-seq. Reads were aligned to the hg19 genome and regions of enriched chromatin accessibility “peaks” were identified with MACS2. For each cell type, we identified the consensus set of epigenetically active peaks across all 14 subjects. We conducted enrichment tests of identified loci using the GREAT tool and performed differential accessibility analysis using the edgeR package in R. Transcription factor binding motif enrichment and overlaps with known SLE risk haplotypes were also determined.

Results: All cell types showed similar percentages (39~43%) of coding transcripts with open chromatin in promoters. The peaks unique to each profile were enriched in genomic loci specific to their cellular function: T cell development/activation for T cells, B cell development/activation for B cells, and phagocytosis, apoptotic cell clearance, and inflammatory cytokine regulation for monocytes. Analysis of transcription factor binding motifs in ATAC peaks identified cell type specific promoters including myeloid and lymphoid cell lineage commitment transcription factors. Quantitative analysis revealed chromatin accessibility loci that discriminate between SLE and controls, as well as between high and low disease activity. Of the total 53338 monocyte specific peaks observed in at least 7 samples, 308 peaks allowed us to differentiate between SLE and controls, whereas in T and B cells the numbers were 57 of 34818 and 553 of 39425, respectively. Motif analysis revealed that many consensus peaks occupy binding sites of cohesin complex subunits, suggesting that long-range chromatin interactions may mediate immune responses that drive SLE progression. In addition, of 2519 SLE genetic risk SNPs, 320 were located within an open chromatin peak suggesting functional relevance.

Conclusion: Our data suggest that SLE and controls show cell type specific differences in their chromatin accessibility, and these profiles differ across the spectrum of disease activity. Chromatin profiling, integrated with transcriptome data, may expand our knowledge of how specific cell states drive SLE pathogenesis.


Disclosure: N. R. Jog, None; R. C. Pelikan, None; M. Bebak, None; J. M. Guthridge, None; J. A. James, None; P. M. Gaffney, None.

To cite this abstract in AMA style:

Jog NR, Pelikan RC, Bebak M, Guthridge JM, James JA, Gaffney PM. Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cell-type-specific-epigenetic-features-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cell-type-specific-epigenetic-features-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology